Abstract: A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof.

Abstract: Hydrophilic dispersions of stable nano-sized particles are provided comprising: (a) a water-insoluble or water-soluble active compound, wherein said active compound is selected from the group consisting of a macrolide antibiotic, donepezil hydrochloride, an azole compound and a taxane; and (b) an amphiphilic polymer which wraps said active compound in a non-crystalline manner to form a nano-sized molecular entity in which no valent bonds are formed.

Abstract: The invention relates to the use of branched chain fatty acids (BFAs) and their derivatives for inhibition of the activity of P-glycoprotein (P-gp). In particular, the invention relates to the use of BFAs and their derivatives in the treatment of multi-drug resistant (MDR) tumors associated with increased activity of P-glycoprotein. The invention also relates to the use of the above-mentioned molecules for administration of biologically active molecules and diagnostic agents into cells associated with increased activity of P-gp, and for increasing accumulation of biologically active molecules and diagnostic agents in organs protected by biological barriers.

Abstract: The anginal medicated compound according to the present invention comprises the active principle 2,4,6,8-tetramethyl-2,4,6,8-tetraazobicyclo-/3,3,0/-octanedione-3,7 of the formula: ##STR1## in combination with a pharmaceutical carrier. The medicated compound according to the present invention is useful for the treatment of patients suffering from ischemic heart disease.